Page 103 - 《中国药房》2023年16期

2019，12（11）：1055-1063. [17] SCHULMAN S，KEARON C，Subcommittee on Control
[ 8 ] ASMARATS L，O’HARA G，CHAMPAGNE J，et al. of Anticoagulation of the Scientific and Standardization
Short-term oral anticoagulation versus antiplatelet therapy Committee of the International Society on Thrombosis
following transcatheter left atrial appendage closure[J]. and Haemostasis. Definition of major bleeding in clinical
Circ Cardiovasc Interv，2020，13（8）：e009039. investigations of antihemostatic medicinal products in
[ 9 ] BELGAID D R，KHAN Z，ZAIDI M，et al. Prospective non-surgical patients[J]. J Thromb Haemost，2005，3（4）：
randomized evaluation of the watchman left atrial appen- 692-694.
dage closure device in patients with atrial fibrillation [18] HIGGINS J P T，ALTMAN D G，GØTZSCHE P C，et al.
versus long-term warfarin therapy：the PREVAIL trial[J]. The Cochrane Collaboration’s tool for assessing risk of
Int J Cardiol，2016，219：177-179. bias in randomised trials[J]. BMJ，2011，343：d5928.
[10] DAWWAS G K，DIETRICH E，CUKER A，et al. Effec‐ [19] STANG A. Critical evaluation of the Newcastle-Ottawa
tiveness and safety of direct oral anticoagulants versus scale for the assessment of the quality of nonrandomized
warfarin in patients with valvular atrial fibrillation：a studies in meta-analyses[J]. Eur J Epidemiol，2010，25
population-based cohort study[J]. Ann Intern Med，2021， （9）：603-605.
174（7）：910-919. [20] DUTHOIT G，SILVAIN J，MARIJON E，et al. Reduced
[11] BERGMANN M W，BETTS T R，SIEVERT H，et al. rivaroxaban dose versus dual antiplatelet therapy after left
Safety and efficacy of early anticoagulation drug regimens atrial appendage closure：adrift a randomized pilot study
after watchman left atrial appendage closure：three-month [J]. Circ Cardiovasc Interv，2020，13（7）：e008481.
data from the ewolution prospective，multicentre，monitored [21] FAROUX L，CRUZ-GONZÁLEZ I，ARZAMENDI D，et
international watchman LAA closure registry[J]. Euro In‐ al. Short-term direct oral anticoagulation or dual antiplate‐
tervention，2017，13（7）：877-884. let therapy following left atrial appendage closure in pa‐
[12] ZHU J，XU J. The use of novel non-vitamin K antagonist tients with relative contraindications to chronic anticoagu‐
oral anticoagulants following closure of the left atrial lation therapy[J]. Int J Cardiol，2021，333：77-82.
appendage：preliminary results of clinical follow-up[J]. [22] CEPAS-GUILLEN P L，FLORES-UMANZOR E，REGUEIRO
Drug Des Devel Ther，2021，15：1067-1073. A，et al. Low dose of direct oral anticoagulants after left
[13] 卢艳钦，李晓烨，张晓春，等. 非瓣膜性心房颤动患者左 atrial appendage occlusion[J]. J Cardiovasc Dev Dis，
心耳封堵术后新型口服抗凝药治疗的疗效与安全性[J]. 2021，8（11）：142.
中国新药与临床杂志，2022，41（9）：543-548. [23] ZHANG Z H，YAO Q，HUANG H Y，et al.Efficacy and
[14] 陈新敬，吴志勇，郭延松，等. 利伐沙班在左心耳封堵术 safety of dabigatran and dual antiplatelet therapy after left
后抗凝方案中的应用[J]. 广州医科大学学报，2021，49 atrial appendage occlusion with the watchman device[J].
（6）：64-67. Int J Clin Exp Med，2018，11（9）：9819-9826.
[15] 黄琼，刘荣，陈立鸿，等. 非瓣膜性心房颤动左心耳封堵 [24] LI X Y，ZHANG X C，JIN Q C，et al. The impact of dabi‐
术后利伐沙班抗凝的临床疗效[J]. 心肺血管病杂志， gatran and rivaroxaban on variation of platelet activation
2021，40（6）：533-537. biomarkers and DRT following percutaneous left atrial
[16] ENOMOTO Y，GADIYARAM V K，GIANNI C，et al. appendage closure[J]. Front Pharmacol，2021，12：723905.
Use of non-warfarin oral anticoagulants instead of warfa‐ （收稿日期：2023-01-30 修回日期：2023-07-09）
rin during left atrial appendage closure with the watchman （编辑：陈 宏）
device[J]. Heart Rhythm，2017，14（1）：19-24.

中国药房 2023年第34卷第16期 China Pharmacy 2023 Vol. 34 No. 16 · 2013 ·